Nkgen Biotech, INC DEF 14A proxy statements
Proxy statements, covering the matters put to shareholders at the annual meeting — board elections, auditor ratification and executive pay.
OTC.Pink
NKGen Biotech is seeking stockholder approval for a reverse stock split to regain compliance with Nasdaq's minimum bid price requirement and potentially improve stock marketability.
OTC.Pink
NKGen Biotech is holding its annual meeting on August 28, 2024, to vote on the election of a director, the potential issuance of shares exceeding 19.99% of outstanding shares, and authorization to adjourn the meeting if necessary.